Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.

Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.

BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analys...

Full description

Bibliographic Details
Main Authors: Wei-Xiang Qi, Qiong Wang, Yan-Ling Jiang, Yuan-Jue Sun, Li-Na Tang, Ai-Na He, Da-Liu Min, Feng Lin, Zan Shen, Yang Yao
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3568141?pdf=render

Similar Items

Similar Items